Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #278614 on Anavex Life Sciences Corp (AVXL)
XenaLives
10/26/20 8:58 AM
#278619 RE: Investor2014 #278614
Results In total, 203 patients entered the study, and 142 completed the 52-week treatment. Adverse events (AEs) occurred in 78.3% of patients, with nasopharyngitis (20.7%) and dyskinesias (17.7%) as the most common; serious AEs occurred in 17.2%, causing discontinuation in 10.8%. At Week 52, the mean daily ON-time without troublesome dyskinesias increased from baseline by 1.42 h. Change from baseline in mean daily OFF-time was -1.40 h, and that in the UPDRS Part III score in the ON-phase was -6.20.
LakeshoreLeo1953
10/26/20 9:44 AM
#278631 RE: Investor2014 #278614